801-531-9168 (ATR 1 8 2023)

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
The persons are required to respond to a collection of information unless it contains a valid CMB control number.

? 十

Substitute for form 1449A/PTQ

TNTODMATION DISCLOST

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Application Number	09/517,898			
Filing Date	March 3, 2000			
First Named Inventor	Vogels et al.			
Group Art Unit	1632			
Examiner Name	Q. Li			
Attomey Docket Number	.2578-3982 2US	フ		

	1		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
		Crystal et al., Transfer of Gene to Human: Early Lessons and Obstacles to Success, 1995, Science, Vol. 270, pp. 404-10.	
		Eck et al., Gene-Based Therapy, 1996 Goodman & Gilman's, pp. 77-101.	
		Gaff et al., Journal of Virology, 1996, pp. 2116-23, Vol. 70.	
		Guzzinan et al., FNAS, 1994, pp. 10732-36, Vol. 91.	
		Kaye et al., A single arrino acid substitution results in a retinoblastoma protein defective in phosphotylation and oncoprotein binding, September 1990, Proc. Natl. Acad. Sci., pp. 6922-26, Vol. 87.	
	į	Lunky et al., Journal of Virology, 1998, pp. 2022-32, Vol. 72.	
\sim		Rudinger et al., Characteristica of the attino acids as components of a poptide hormone sequence, 1976, Peptide Hormones, pp. 1-7.	
*		Su, ct al., A Genetically Modified Adenoviral Vector Exhibits Bahancod Gene Transfer of Human Smooth Muscle Cells, Journal of Vascular Research 2001, pp. 471-78, Vol. 38.	
8		Wickham et al., Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Protein, Nov. 1997, Journal of Virology, pp. 8221-29, Vol. 71, No. 11.	
*-		Wilson et al., Adenovirus Ventors In the Development of Gene Therapy, 1999, Priedman, T. ed. CSHL Press, Cold Spring Harbor, New York.	_

Examiner	1 Dane	Date	1/2/100	
Signature		Considered	6/26/03	

^{*}EXAMINER: Initial if reference considered, whether or not cirction is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SUND TO: Commissioner for Patents. Washington, DC 20231.